Westmore · UDRP DecisionDulcolax.xyz
The Panel ordered transfer of <dulcolax.xyz>, finding it identical to the Complainant’s DULCOLAX marks, that the Respondent lacked rights or legitimate interests, and that the Respondent registered and used it in bad faith to divert users to a for-profit online pharmacy selling competing or unrelated pharmaceuticals.
The timeline behind dulcolax.xyz
Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.
Westmore reconstructs the full history behind dulcolax.xyz — from public RDAP and the Internet Archive — as part of UDRP Intelligence:
The Respondent, a pharmaceutical seller, knew of the DULCOLAX marks and deliberately used the domain’s goodwill to attract users to a for-profit online pharmacy selling competing or unrelated pharmaceuticals.
Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.
Case number CAC-UDRP-101036 Time of filing 2015-08-14 13:04:13 Domain names dulcolax.xyz Case administrator Name Lada Válková (Case admin) Complainant Organization BOEHRINGER INGELHEIM Pharma GmbH & Co. KG Complainant representative Organization Nameshield (Anne Morin) Respondent Organization SKYRXSHOP Other Legal Proceedings The Panel is not aware of any other legal proceedings that are pending or have been decided and that relate to the disputed domain name. Identification Of Rights The Complainant owns several trademarks, among which: - the international word mark DULCOLAX n° 165781, registered on 10 December 1952 for goods of classes 1 and 5; - the international figurative mark DULCOLAX n° 937960, registered on 16 August 2007 for goods of class 5; Factual Background FACTS ASSERTED BY THE COMPLAINANT AND NOT CONTESTED BY THE RESPONDENT: Boehringer Ingelheim Pharma GmbH & Co. KG is a family-owned pharmaceutical group of companies with roots going back to 1885, when it was founded by Albert Boehringer (1861-1939) in Ingelheim am Rhein. Ever since, BOEHRINGER INGELHEIM has become a global research-driven pharmaceutical enterprise and has today about 140 affiliated companies world-wide, with roughly 46,000 employees. The two main business areas of Boehringer are: Human Pharmaceuticals and Animal Health. In 2013 alone, net sales of the Boehringer group of companies amounted to about EUR 14.1 billion. DULCOLAX is a stimulant laxative drug that produces a bowel movement. The generic term for the drug sold under the trademark DULCOLAX is “BISACODYL”. The Complainant is also the owner of an important portfolio of domain names including the trademark DULCOLAX, of which the domain name <dulcolax.com> registered on 2 December 1997. The disputed domain name <dulcolax.xyz> was registered on 3 August 2015 by the Respondent. Parties Contentions NO ADMINISTRATIVELY COMPLIANT RESPONSE HAS BEEN FILED. Rights The Complainant has, to the satisfaction of the Panel, shown the Domain Name is identical or confusingly similar to a trademark or service mark in which the complainant has rights (within the meaning of paragraph 4(a)(i)of the Policy). No Rights or Legitimate Interests The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the Domain Name (within the meaning of paragraph 4(a)(ii)of the Policy). Bad Faith The Complainant has, to the satisfaction of the Panel, shown the Domain Name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii)of the Policy). Procedural Factors The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision. Principal Reasons for the Decision 1. The Domain name is identical to the DULCOLAX trademarks of the Complainant. The disputed domain name <dulcolax.xyz> is identical to the DULCOLAX trademarks of the Complainant. Indeed, the domain name includes in its entirety the trademark without any adjunction of letter or word. The new gTLD extension “.XYZ” is not sufficient to escape the finding that the domain name is identical to the DULCOLAX trademarks of the Complainant. The Panel finds that the Complainant established that the disputed domain name <dulcolax.xyz> is identical to his prior DULCOLAX trademarks. 2. The Respondent does not have any rights or legitimate interest in the domain name(s) According to WIPO D2003-0455 Croatia Airlines d. d. v. Modern Empire Internet Ltd., the Complainant is required to make out a prima facie case that the Respondent lacks rights or legitimate interests. Once such prima facie case is made, the Respondent carries the burden of demonstrating rights or legitimate interests in the domain name. If the Respondent fails to do so, the Complainant is deemed to have satisfied paragraph 4(a) (ii) of the UDRP. The information regarding the Respondent, provided by the Whois of the disputed domain name <dulcolax.xyz>, is "SKYRXSHOP". A Respondent is not commonly known by a disputed domain name if the Whois information is not similar to the disputed domain name. Thus, the Respondent is not known as "DULCOLAX". The Complainant sufficiently establishes that the Respondent has no rights or legitimate interests in respect of the domain name <dulcolax.xyz> and is not related in any way with the Complainant. The Complainant does not carry out any activity for, nor has any business with the Respondent. Neither a licence nor an authorization has been granted to the Respondent to make any use of the Complainant’s trademarks DULCOLAX, or apply for registration of the disputed domain name by the Complainant. On the contrary, the Respondent “SKYRXSHOP” describes itself as “Your reliable supplier of generic medications.” on its website http://www.skyrxshop.com/ into which redirects the disputed domain name <dulcolax.xyz>. Thus, the Respondent knows the pharmaceutical sector very well and could therefore not ignore the Complainant's trademark DULCOLAX. The Respondent was necessarily informed of this trademark when it registered the disputed domain name <dulcolax.xyz>. The disputed domain name redirects to a page from the website http://www.skyrxshop.com/ On this page, the Respondent sells drugs under the title "Generic Dulcolax (Bisacodyl)". According to the description, the Respondent sells a generic drug (Bisacodyl) from the drug "Dulcolax". The Respondent’s website also offers for sale many other pharmaceutical products, and so is attracting Internet users through the reputation of the Complainant’s trademark, who are then offered a wide range of unrelated products. The Complainant has, to the satisfaction of the Panel, shown that the Respondent was seeking to use the domain name only to divert the consumers to his website and that the Respondent has no legitimate interests in respect of the disputed domain name <dulcolax.xyz>. 3. The domain name(s) has been registered and is being used in bad faith The Complainant successfully asserts that the Respondent was necessarily aware of the trademark DULCOLAX® when it registered the disputed domain name <dulcolax.xyz>. This is confirmed by the content of the website into which the disputed domain name redirects. Indeed, the website in relation with the disputed domain name <dulcolax.xyz> sells drugs under the title "Generic Dulcolax". The Respondent is in the business of the sale of pharmaceuticals, and no doubt knew of the Complainant’s trademarks at the time of registration of the disputed domain name, and deliberately sought to use their goodwill to attract Internet users seeking the Complainant’s product. The Respondent has registered and used the disputed domain names in order to deceive Internet users seeking the Complainant’s product, so as to generate revenue from selling unrelated or competing pharmaceuticals. This constitutes bad faith registration and use within the meaning of the Policy. There is also evidence of bad faith use, in that the Respondent is using the disputed domain name to direct Internet traffic to a for-profit on-line pharmacy that sells pharmaceuticals that directly compete with Complainant. Accordingly, the Complainant has shown, to the satisfaction of the Panel, that the domain name was registered and is being used in bad faith. For all the reasons stated above, the Complaint is Accepted and the disputed domain name(s) is (are) to be DULCOLAX.XYZ: Transferred PANELLISTS Name Tom Heremans Date of Panel Decision 2015-09-24 Publish the Decision
Source of record: CAC . Reproduced for research; CAC is the authoritative source.
What Westmore sees around dulcolax.xyz
The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.

A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.
Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.
The decision is only the beginning.
You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.
Go beyond the public record: see how this case has been cited, find comparable decisions, analyze the panelist and apply the relevant authorities to your Matter.
Westmore Professional · $395/month
Research with UDRP IntelligenceWestmore AI drafts an attorney-review-ready UDRP response from your facts, grounded in the exact panel and closest precedent.
$895 one-time per matter · no subscription required. Self-help drafting aid — not legal advice.
Build your responseWestmore UDRP records draw on CAC-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.